Letter from Joelle Tanguy Director of
Advocacy and Public Affairs, Global Alliance for TB Drug Development
It was a pleasure to meet you at the home of
Sir Thomas Harris, and I hope you had excellent visits in New
York and Geneva. At the request of Lord Soulsby, I am enclosing
information pertaining to the need for new tuberculosis drugs,
and thank you for the opportunity to contribute to the review
of the House of Lords Subcommittee.
As you well know, the tuberculosis epidemic,
now infecting one in three people around the world, is spreading
at alarming rates and kills one person every 15 seconds. Yet no
new drugs were developed for 30 years and the length of treatment
imposed by these older drugs actually hinder the progress and
effectiveness of a TB control program. Furthermore, the lack of
a novel chemical entity makes multi-drug resistant tuberculosis
a deadly threat.
Today, all the pieces are in place for partnering
in a reinvigorated research and development environment to address
this widely recognised medical need. Indeed, the promising advances
in science, the unprecedented momentum in public and private sectors,
and the laser-sharp focus of the Global Alliance for TB Drug Developmentwith
support globallycan make this goal a reality.
We hope the story here inspires the committee
to consider the recommendations of the Stop TB Partnership to
view the TB epidemic not only as a critical issue of access to
properly managed and patient-focused treatment, but also as a
result of an imbalance in research agendas that has left TB practitioners
with 100 year old diagnostics and 30 year old therapeutic tools.
Reversing this and finding a new, fast-acting cure for TB are
integral priorities in both global and local fights against the
We are very eager to explore ways to support
the work of the House of Lords Subcommittee and wish you the very
best in this very important initiative.